<i>In Vitro</i> Activity of Cefepime-Taniborbactam against Carbapenemase-Producing <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates Recovered in Spain

Abstract

Novel β-lactam–β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime–VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales ( n = 247) and carbapenem-resistant Pseudomonas species ( n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MIC FTB , ≤8/4 mg/L) and Pseudomonas (67.1% MIC FTB , ≤8/4 mg/L) populations.